Description

Acabrunat 100 mg (Acalabrutinib) – Next‑Gen BTK Inhibitor for B‑cell Malignancies

Acabrunat 100 mg is a branded generic of acalabrutinib, manufactured by Natco Pharma in India. It’s a selective oral BTK inhibitor approved for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), used either as monotherapy or with rituximab/bendamustine or obinutuzumab based on indication and prior treatment. 

⚙️ Mechanism

Acalabrutinib irreversibly binds Bruton’s tyrosine kinase (BTK), interrupting malignant B-cell signaling and halting disease progression. It features higher selectivity and fewer off-target effects than first-gen BTK inhibitors, translating to fewer side effects.

🩺 Dosing & Administration

• Standard dosing: 100 mg orally twice daily (~12‑hour interval), with or without food. Do not crush or chew. 
• Continue therapy until disease progression or unacceptable toxicity.
• Adjust dose with CYP3A inhibitors (reduce to once daily) or inducers (increase to 200 mg BID). Space acid‑reducing medications by ≥2 hours. 

🩺 Indications

• Monotherapy in relapsed/refractory MCL or untreated CLL/SLL
• Combo with rituximab & bendamustine (MCL) or obinutuzumab (CLL/SLL) per prescribing regimens. 

⚠️ Adverse Effects & Monitoring

• **Common**: headache, fatigue, diarrhea, cytopenias (neutropenia, anemia). 
• **Severe**: atrial fibrillation (~7%), bleeding (~5%), hypertension (~7%), infection (~11%). Hepatic injury possible—monitor LFTs. ([turn0search18], [turn0search0])
• Monitor CBC, LFTs, kidney function & ECG periodically. Avoid in severe hepatic impairment. 

✅ Benefits of Choosing Acabrunat

• Equivalent efficacy to branded Calquence at a lower cost. 
• Twice-daily capsules support outpatient compliance—no infusion needed.
• Gentler safety profile vs earlier BTK inhibitors—ideal for long-term use. 

❓ FAQs

1. What if a dose is missed?

If missed by < 3 hours, take it. If more, skip and resume next scheduled dose. Do not double. 

2. Can this be taken with antacids or PPIs?

Tablet formulations may be taken with PPIs safely. Capsules should be spaced ≥2 hours from acid reducers. 

3. How soon will it work?

Clinical responses—including lymphocyte count reductions—may begin within weeks; full disease control may take several months. 

4. Do older patients tolerate it well?

Yes—trials have shown tolerability in elderly populations with fewer off-target effects than first-generation BTK inhibitors. 

5. Is long-term use safe?

With regular monitoring and managing toxicity, acalabrutinib is generally safe for long-term use in chronic indications.